Precision BioSciences Inc... (DTIL)
NASDAQ: DTIL
· Real-Time Price · USD
4.30
0.16 (3.86%)
At close: Jun 27, 2025, 3:59 PM
4.28
-0.47%
After-hours: Jun 27, 2025, 05:26 PM EDT
3.86% (1D)
| Bid | 4.24 |
| Market Cap | 47.79M |
| Revenue (ttm) | 51.14M |
| Net Income (ttm) | -21.99M |
| EPS (ttm) | -2.87 |
| PE Ratio (ttm) | -1.5 |
| Forward PE | -0.89 |
| Analyst | Buy |
| Ask | 4.35 |
| Volume | 342,740 |
| Avg. Volume (20D) | 261,048 |
| Open | 4.20 |
| Previous Close | 4.14 |
| Day's Range | 4.03 - 4.38 |
| 52-Week Range | 3.61 - 11.09 |
| Beta | 1.47 |
About DTIL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol DTIL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for DTIL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Precision BioSciences Inc. is scheduled to release its earnings on Jul 31, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 days ago
-7.22%
DTIL stock has given up its prior gain. Precision ...
Unlock content with
Pro Subscription
2 days ago
-7.22%
Precision BioSciences shares are trading higher after the company received FDA Rare Pediatric Disease Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy.
1 month ago · businesswire.com
Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
